STATUS OF ASSESSMENTS

The table below lists the status of prioritized health technologies for HTA. Prioritized topics refer to health technologies that adhered to HTAC’s standard set of criteria responding to the priority health care needs of the country.

 

Definitions of each status:

  • Assessment refers to the application of formal scientific methods of evidence synthesis to assess the clinical, economic, health system, ethical, legal and social impact of covering or disinvesting a particular health technology in the local Philippine context.
  • Initial findings of the Assessment for Public Consultation refers to the key findings of the Assessment, which will be available for public consultation.
  • Preliminary Recommendation refers to the initial recommendation issued by HTAC through a deliberative process of assessing the quality and the strength of the evidence guided by a decision framework aligned with the UHC law. Preliminary recommendation is made based on the results of the Assessment, and the inputs of stakeholders during the public consultation. After its release, the preliminary recommendation shall be open for appeals. Appeals refers to the process where all stakeholders are allowed to submit any comments, appeals, or requests for reconsideration within 10 working days based on any of the following grounds:
      • Not all relevant evidence has been considered by HTAC
      • New additional evidence that could influence the recommendation of HTAC
      • A new price offer from the manufacturer of the product to ensure its affordability to DOH and PHIC.
  • Final Recommendation refers to the recommendation by HTAC upon consideration of appeals on a particular health technology.
  • Decision refers to the process of decision-making based on transmitted recommendation of the HTAC to the Secretary of Health and the PHIC Board of Directors for health interventions that are within their remit. The Secretary of Health and the PHIC Board of Directors shall provide an issuance in response to the transmitted recommendation of HTAC.

Note: In the event of a declared Public Health Emergency (e.g., COVID-19), status of health technologies (i.e., those that potentially respond to the said health emergency) will only be Assessment, Recommendation, and Decision. The Philippine HTA Process Guide elaborates both HTA processes during normal circumstances and during Public Health Emergencies.

Table of Assessments

Name of health technology Type of health technology Assessment Status Recommendation Status Decision Status Date of Publication
Fourth dose of COVID-19 Vaccines among the immunocompromised population (ICPs)Vaccines, Preventive and promotive health services Complete Complete Available 21 April 2022
tocilizumab for the treatment of COVID-19Drugs Complete Complete Available 11 May 2022
Potassium Citrate [1620 mg (15mEq)] tabletDrugs Complete Complete Available 11 May 2022
Pfizer-BioNTech (10ug/dose) COVID-19 Vaccine for Children 5 to 11 Years OldVaccines, Preventive and promotive health services Complete Complete Available 11 February 2022
Emtricitabine + Tenofovir DisoproxilFumarate fixed-dose combination as OralPre-Exposure Prophylaxis (PrEP) toreduce the risk of sexually acquired HIVinfectionDrugs Complete Complete Available 17 December 2021
Vasopressin 20 I.U./mL (I.V./I.M./S.C.)Drugs Complete Complete Available 02 March 2022
Sambong 250mg tablet for anti-urolithiasis (kidney stones)Other Health Technologies Complete Complete Available 14 January 2022
Booster and Additional Dose Vaccination for the prevention of COVID-19Vaccines, Preventive and promotive health services Complete Complete Available 03 November 2021
Sputnik V Gam-COVID-Vac COVID-19 Vaccine for the prevention of COVID-19(December Reassessment)Vaccines, Preventive and promotive health services Complete Complete Available December 14, 2021
Covovax for the prevention of COVID-19Vaccines, Preventive and promotive health services Complete Complete Available December 14, 2021
Whole Virion, Inactivated Corona Virus [Covaxin] for the prevention of COVID-19Vaccines, Preventive and promotive health services Complete Complete Available November 29, 2021
COVID-19 Vaccine Sinopharm for the prevention of COVID-19Vaccines, Preventive and promotive health services Complete Complete Available November 29, 2021
Two-dose Inactivated Polio Vaccine (IPV) versus One-dose IPV for the prevention of PoliomyelitisVaccines, Preventive and promotive health services Complete Complete Available July 13, 2021
Use of casirivimab+imdevimab for the treatment of COVID-19Drugs Complete Complete Available 24 December 2021
Tenofovir/Lamivudine/Dolutegravir for treatment-naive and treatment-experienced adolescents and adults living with HIVDrugs Complete Complete Available August 24, 2021
RapidAntigen Test Kits for the Diagnosis ofCOVID-19 (September 2021 Updates)Clinical equipment and devices Complete Complete Available 27 September 2021
Use of RT-PCR Testing for COVID-19 (April 2021 Reassessment)Clinical equipment and devices Complete Complete Available 30 April 2021
SARS-CoV-2Vaccine (Vero Cell), Inactivated[CoronaVac] for the prevention ofCOVID-19 (July Updates)Vaccines, Preventive and promotive health services Complete Complete Available 30 July 2021
Sputnik V, Pfizer - BioNTech, Janssen, AstraZeneca(June Reassessments)Vaccines, Preventive and promotive health services Complete Complete Available 25 June 2021
Rapid antibody tests (RATs)(May 2020 reassessment)Clinical equipment and devices Complete Complete Available 01 August 2020
Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR)Clinical equipment and devices Complete Complete Available 18 May 2020
AMTI uAI-Discover-PNAClinical equipment and devices Complete Complete Available 14 April 2020
FavipiravirDrugs Complete Complete Available 08 April 2020
CycloferonDrugs Complete Complete Available 07 April 2020
Huawei Cloud AI-Assisted DiagnosisClinical equipment and devices Complete Complete Available 13 April 2020
Rapid antibody tests (RATs)(March 2020 assessment)Clinical equipment and devices Complete Complete Available 25 March 2020
Use of Pooled Testing for the screening and surveillance of COVID-19Clinical equipment and devices Complete Complete Available 28 October 2020
Use of Rapid Antigen test kits for the diagnosis of COVID-19Clinical equipment and devices Complete Complete Available 02 October 2020
Extracorporeal Membrane Oxygenation (ECMO) for COVID-19 patients with ARDSClinical equipment and devices, Medical and surgical procedures Complete Complete Available 10 September 2020
COVID-19 MRNA Vaccine (Nucleoside Modified) (COVID-19 Vaccine Moderna) for the prevention of COVID-19Vaccines, Preventive and promotive health services Complete Complete Available 28 May 2021
High-Flow Nasal Cannula Oxygen Therapy for the treatment of Acute Hypoxemic Respiratory Failure for COVID-19Clinical equipment and devices, Medical and surgical procedures Complete Complete Available 01 December 2020
COVID-19 Vaccine (ChAdOx1-S [recombinant]) (COVID-19 Vaccine AstraZeneca) for the prevention of COVID-19Vaccines, Preventive and promotive health services Complete Complete Available 08 February 2021
SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac]Vaccines, Preventive and promotive health services Complete Complete Available 09 April 2021
Sputnik V Gam-COVID-Vac COVID-19 VaccineVaccines, Preventive and promotive health services Complete Complete Available 12 April 2021
BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) for the prevention of COVID-19Vaccines, Preventive and promotive health services Complete Complete Available 02 February 2021
Pneumococcal Conjugate Vaccine 13 (PCV-13)(2020 Reassessment)Vaccines Complete Complete Available 01 July 2020
Janssen Ad26.COV2.S (COVID-19) Vaccine for the prevention of COVID-19Vaccines, Preventive and promotive health services Complete Complete Available 30 April 2021
Use of Rapid Antigen Test Kits for the Diagnosis of COVID-19 (April 2021 Assessment)Clinical equipment and devices Complete Complete Available 30 April 2021